Proud to be a researcher of this great kidney cancer genome project efforts for more than 2 years will impact the future of #RenalCellCarcinoma #CancerResearch #scRNAseq is presented #AUA24 Amer. Urol. Assn. Simon Tanguay Yasser Riazalhosseini Fadi Brimo McGill Genome RI-MUHC McGill University

Advanced or metastatic #renalcellcarcinoma can be a hard-to-treat cancer. We are committed to researching and delivering efficacious options that may help improve long-term outcomes for patients with advanced disease. #GU24 bit.ly/3vJtf2P

Learn more about our latest update in #RenalCellCarcinoma : merck.us/3scNPHn

Hello #urology #residents !

Here is the flowchart for #renalcellcarcinoma . From diagnosis to treatment of metastatic disease.
(according to the 2022 guidelines)
Looking forward for the 2023 Guidelines 🙂
Free download at knowuro.com/goodies

Updated 📢 #RenalCellCarcinoma : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Assessing mature data for first-line metastatic trials as well as sequencing strategies & new agents such as belzutifan. ow.ly/nZA050RP77l
#kcsm @silke_gillessen

#MEDIA : Announcing positive results from our Phase 3 noninferiority trial of a subcutaneous formulation of a PD-1 agent in patients with advanced or metastatic clear cell #renalcellcarcinoma . bit.ly/45BJT0y

As #InterventionalOncology section editor for Current Oncology Reports, I would like to share an article that is hot off the press! Important work by Drs. Alyssa Knight and AJ Gunn from UAB IR on the current role of percutaneous ablation of T1b #renalcellcarcinoma . Due to

Today, we presented new late- breaking data from a Phase 3 trial of our #immunotherapy in earlier stages of #RenalCellCarcinoma . Learn more here: merck.us/47Uzvlz

#MEDIA : Announcing four-year results from our Phase 3 combination therapy trial with Exelixis in patients with advanced #renalcellcarcinoma at ASCO #GU24 . bit.ly/47N3v2P

#MEDIA : Announcing 8-year data at ASCO #GU24 from our Phase 3 trial for an #immunotherapy combination in previously untreated advanced or metastatic #renalcellcarcinoma , the longest reported follow up in this patient population. bit.ly/3StbAoO

Cracking the #RenalCellCarcinoma code:
🔘Identifying established risk factors like smoking, obesity & hypertension is crucial.
🔘Paradoxically, obesity can aid survival in advanced stages.
🔘Hypertension's role needs clarity.
🔘More studies are required on diet, exercise, &

#NewResearch w/ de-identified data from patients who underwent Foundation Medicine’s liquid biopsy testing identified circulating tumor DNA tumor fraction as a prognostic marker in metastatic #RenalCellCarcinoma patients. More on this research here bit.ly/42b6uAS #GU24

Results of SWOG Cancer Research Network S0931 EVEREST trial of adjuvant everolimus in #RenalCellCarcinoma , now in The Lancet. PI Christopher Ryan, MD, OHSU News comments on implications. #kcsm Lucky Lara Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Ulka Vaishampayan Benjamin L Maughan Brian Shuch, MD Neeraj Agarwal, MD, FASCO sciencedirect.com/science/articl…

Case 135: Cryoablation of Renal Cell Carcinoma

75-yrs old with a > 4 cm solid renal lesion.

Video and discussion
ctbiopsy.com/case135/

#ctbiopsy #irrad #cryoablation #renalcellcarcinoma #renalcryoablation

🔬🏥 New Study Reveals: Cytoreductive Nephrectomy Safe for Advanced Kidney Cancer Patients Undergoing Immunotherapy! 🛡️💉
🔘Use of these agents do not significantly contribute to additional postoperative surgical risk.
#CancerTreatment #RenalCellCarcinoma
OncoAlert UroToday.com

SCI member James Brooks and others found that #MassSpectrometry imaging combined with #MachineLearning may be a better way to determine surgical margins in #RenalCellCarcinoma bit.ly/3skPpGJ

Appreciate David Braun’s ending note - listen to the #patientperspective ASCO #ASCO23 #patientadvocate #kidneycancer #renalcellcarcinoma

The optimal approach for the management of brain metastases from #RenalCellCarcinoma remains unclear. To improve patient care, the authors of this #OpenAccess review sought to standardize practical management strategies.

acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

OncoAlert
#GU24

According to researchers, a new analysis of the Phase III KEYNOTE-564 study demonstrated the first survival benefit in adjuvant therapy for #RenalCellCarcinoma seen in 50 years of clinical trials. Read more: ow.ly/8Soc50RzE4h #RCC

In our latest clinical update, we summarise the two ongoing gene-editing clinical trials for renal cell carcinoma, which is the most common form of kidney cancer found in adults.

Read it here: bit.ly/3J0uf6O

#crisprmedicine news #crisprmedicine #renalcellcarcinoma